Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Jinshan Nan und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. Hauptthemen laut MEDLINE: Cannabinoid Receptor Agonists, Cannabinoids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Department of Science and Technology of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Selectively targeting the cannabinoid receptor CB2 is an attractive therapeutic strategy for the treatment of inflammatory pain without psychiatric side effects mediated by the cannabinoid receptor CB1. Herein, we report the discovery of 4-(1,2,4-oxadiazol-5-yl)azepan-2-one derivatives as a new class of CB2 agonists. Systematic structure-activity relationship investigations resulted in the identification of the most potent compound 25r. This compound displayed high selectivity for CB2 against CB1 (CB2 EC50 = 21.0 nM, Emax = 87%, CB1 EC50 > 30 μM, ratio CB1/CB2 > 1428) with favorable pharmacokinetic properties. Especially, 25r demonstrated significant efficacy in the analgesic model of rodent inflammatory pain. All the results suggest that compound 25r could serve as a lead compound for treating inflammatory pain and deserves further in-depth studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China.
- Key Laboratory of General Chemistry of the National Ethnic Affairs Commission, School of Chemistry and Environment, Southwest Minzu University, Chengdu Sichuan 610041, China.
ORCID-Profile: Anjie Xia, Shengyong Yang
Förderung
- China Postdoctoral Science Foundation
- Department of Science and Technology of Sichuan Province
- National Natural Science Foundation of China
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
- Post-Doctor Research Project, West China Hospital, Sichuan University
Zitieren
APA
Nan, J., Liu, J., Lin, G., Zhang, S., Xia, A., Zhou, P., Zhou, Y., Zhang, J., Zhao, J., Zhang, S., Huang, C., Wang, Y., Hu, Q., Chen, J., Xiang, M., Yang, X., & Yang, S. (2023). Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01943
Vancouver
Nan J, Liu J, Lin G, Zhang S, Xia A, Zhou P, et al. Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01943
BibTeX
@article{Nan2023,
author = {Nan, Jinshan and Liu, Jingming and Lin, Guifeng and Zhang, Shanshan and Xia, Anjie and Zhou, Pei and Zhou, Yangli and Zhang, Jiahao and Zhao, Jinlong and Zhang, Shiyu and Huang, Chong and Wang, Yifei and Hu, Qian and Chen, Junxian and Xiang, Mingli and Yang, Xin and Yang, Shengyong},
title = {Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01943}
}
EUVIMED